The COVID-19 pandemic is causing major problems to cancer research. The risk is the disruption of progress made over the last few years with dramatic consequences on patient care and outcomes. This is particularly serious for pancreatic cancer, the deadliest solid tumour, for which accelerating research is tremendously important.
The Glasgow Precision Oncology Laboratory (GPOL – University of Glasgow), in collaboration with the Italian Pancreatic Cancer Community (I-PCC), the Pancreas Institute of Verona (University of Verona), and the Preclinical Dutch Pancreatic Cancer Group (DPCG – Netherlands) launched a survey to investigate the current and expected impact of COVID-19 pandemic on pancreatic cancer research worldwide.
The survey is addressed to group leaders/principal investigators working on preclinical and translational research in academic and non-academic research institutes and is part of a wider project evaluating the consequences of pandemic on pancreatic cancer through a transversal, transdisciplinary approach.
This evidence will inform the design of interventions to guarantee research and protect researchers. Considering the current situation, possible second lockdowns in many countries, and the persistence of COVID-19 pandemic for an indefinite time, these actions will be important to prevent the potential dramatic long-term consequences on pancreatic cancer research.
We invite all group leaders/principal investigators involved in pancreatic cancer preclinical/translational research to respond to this short survey (fewer than 3 minutes).
For more information about this research please contact Dr. Raffaella Casolino email@example.com